SEC Comment Letter 0000000000-23-001272 to Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: Feb. 7, 2023 · CIK: 0001671502 · Accession: 0000000000-23-001272
AI Filing Summary & Sentiment
File numbers found in text: 333-269543
Letter
United States securities and exchange commission logo February 7, 2023 Dr. Michael Myers Chief Executive Officer Quoin Pharmaceuticals, Ltd. 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Re:Quoin Pharmaceuticals, Ltd. Registration Statement on Form S-1 Filed February 3, 2023 File No. 333-269543 Dear Dr. Michael Myers: We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Registration Statement on Form S-1 Cover Page 1.When available, please revise your prospectus cover page to clarify the number of ADSs, pre-funded warrants, common warrants and ordinary shares being offered. 2.Please revise your prospectus cover page to disclose the date on which the offering will terminate. For guidance, please refer to Item 501(b)(8)(iii) of Regulation S-K. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
FirstName LastNameDr. Michael Myers Comapany NameQuoin Pharmaceuticals, Ltd. February 7, 2023 Page 2 FirstName LastName Dr. Michael Myers Quoin Pharmaceuticals, Ltd. February 7, 2023 Page 2 time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Jessica Ansart at 202-551-4511 or Celeste Murphy at 202-551-3257 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Yelena M. Barychev
Show Raw Text
United States securities and exchange commission logo
February 7, 2023
Dr. Michael Myers
Chief Executive Officer
Quoin Pharmaceuticals, Ltd.
42127 Pleasant Forest Court
Ashburn, VA 20148-7349
Re:Quoin Pharmaceuticals, Ltd.
Registration Statement on Form S-1
Filed February 3, 2023
File No. 333-269543
Dear Dr. Michael Myers:
We have limited our review of your registration statement to those issues we have
addressed in our comments. In some of our comments, we may ask you to provide us with
information so we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.
Registration Statement on Form S-1
Cover Page
1.When available, please revise your prospectus cover page to clarify the number of ADSs,
pre-funded warrants, common warrants and ordinary shares being offered.
2.Please revise your prospectus cover page to disclose the date on which the offering
will terminate. For guidance, please refer to Item 501(b)(8)(iii) of Regulation S-K.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
FirstName LastNameDr. Michael Myers
Comapany NameQuoin Pharmaceuticals, Ltd.
February 7, 2023 Page 2
FirstName LastName
Dr. Michael Myers
Quoin Pharmaceuticals, Ltd.
February 7, 2023
Page 2
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Jessica Ansart at 202-551-4511 or Celeste Murphy at 202-551-3257 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Yelena M. Barychev